Improving Profitability Supports Sarepta Therapeutics Inc. (SRPT) as One of the Most Shorted Small-Cap Stocks to Buy

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 6, Sarepta Therapeutics Inc. (NASDAQ:SRPT) delivered impressive first-quarter results as it bounced back to profitability despite facing commercialization challenges with its flagship gene therapy, ELEVIDYS.

Improving Profitability Assert Sarepta Therapeutics Inc (SRPT) as One of the Most Shorted Small Cap Stocks to Buy

Total revenue in the quarter was $730.8 million, a decrease of $14.1 million from $744.9 million delivered in the same quarter last year. The decline was attributed to lower ELEVIDYS sales volume resulting from the updated label, which specifies treatment only for ambulatory patients. The decrease was partially offset by a $253 million increase in collaboration revenue.

Amid a slight revenue decline, Sarepta Therapeutics bounced back to profitability with non–GAAP net income of $385.4 million, or $3.16 a share, compared to a net loss of $332.5 million, or a loss of $3.42 a share, delivered the same quarter last year. Earnings beat analysts’ expectations of $0.99 a share on revenue of $731 million.

The bounce back to profitability was driven by disciplined cost management and a favorable revenue mix. In addition, the company delivered positive cash flow, with cash and investments totaling $748 million. Consequently, it remains well-positioned to fund its pipeline development without tapping the debt market.

Sarepta Therapeutics Inc (NASDAQ:SRPT) is a global biotechnology company that engineers precision genetic medicines to treat rare neuromuscular diseases, primarily Duchenne muscular dystrophy (DMD). They develop treatments using three main scientific platforms: gene therapy, RNA technologies, and gene editing.

While we acknowledge the risk and potential of SRPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SRPT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Top 10 Small Cap Stocks With Huge Growth Potential and Renaissance Technologies Returns, AUM, CEO and Top 10 Semiconductor Stock Picks.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1